Peter M. Glazer, MD, PhD

Robert E. Hunter Professor of Therapeutic Radiology and Professor of Genetics; Chair, Department of Therapeutic Radiology

Research Interests

DNA Repair; Genetics; Radiation; Mutagenesis; Gene Targeting; Radiation Oncology; Recombinational DNA Repair

Research Organizations

Therapeutic Radiology: Glazer Lab | Radiobiology | Therapeutic Radiology - Research

Center for RNA Science and Medicine, Yale

Faculty Research

School of Public Health

Skin Diseases Research Center, Yale

Yale Cancer Center: Radiobiology & Radiotherapy

Office of Cooperative Research

Research Summary

Gene targeting via triple helix formation: From an interest in studying cellular DNA repair and recombination pathways, we recognized the utility of DNA triple helix formation as a mechanism for the site-specific induction of recombination in human cells. We have recently demonstrated that triplex forming oligonucleotides can be used to mediate targeted modification of human disease-related genes. We are currently optimizing this approach for application in human hematopoietic stem cells and in mouse models of human genetic diseases.

Tumor hypoxia, genetic instability, and cancer therapy: We discovered that tumor hypoxia is a key driver of genetic instability in human cancer cells. Mechanistically, we determined that this instability arises because of suppression of the DNA mismatch repair and homology dependent repair pathways, due to specific repression of the MLH1 and BRCA1, genes, respectively. This down-regulation of DNA repair in hypoxic cancer cells renders them vulnerable to therapeutic strategies that exploit the specific repair deficiencies, providing the basis for novel, rationally designed cancer therapies.

Specialized Terms: Gene targeting and gene therapy; Genetic instability in cancer; Mutagenesis; DNA repair; Radiation resistance; Cellular responses to radiation

Extensive Research Description

Gene targeting via triple helix formation
From an interest in studying cellular DNA repair and recombination pathways, we recognized the utility of DNA triple helix formation as a mechanism for the site-specific introduction of DNA damage in mammalian cells. Using psoralen-conjugated triplex-forming oligonucleotides, we initially demonstrated the feasibility of triplex-targeted mutagenesis in several model systems. We were able to determine conditions under which triplex oligonucleotides can enter cells and efficiently bind to and modify a target site within cells, leading to base pair specific mutations. Experiments with oligonucleotides not tethered to a reactive agent but capable of high affinity third strand binding revealed that triple helix formation can induce DNA repair and recombination in mammalian cells. This work has raised the possibility of using triplex formation as both a gene knock out and a gene correction modality. It has also suggested that unusual DNA structures may provoke repair activity and may contribute to genomic instability. We are currently studying the feasibility of targeting chromosomal genes using this approach, either by directly inducing mutations in the target gene or by stimulating recombination in a site-directed manner.

Tumor hypoxia, genetic instability, and tumor progression
We hypothesized that that acquired genetic instability in cancer cells may arise from the dysregulation of critical DNA repair pathways due to cell stresses within the tumor microenvironment such as hypoxia. We initially confirmed this hypothesis by measuring mutation frequencies in experimental tumors using a lambda-based chromosomal shuttle vector reporter system. To elucidate the mechanism underlying this phenomenon we used a microarray-based approach to screen for hypoxia-regulated DNA repair pathways. We found that hypoxia specifically down-regulates the expression of Mlh1 and Rad51, key mediators of DNA mismatch repair and of homologous recombination in mammalian cells, respectively. Down-regulation of Mlh1 and Rad51 expression by hypoxia was observed in numerous cell lines from a wide range of tissues, and was not correlated with cell cycle profile or hypoxia-inducible factor expression. Rad51 down-regulation was also detected in vivo in the tumor microenvironment, as we observed consistent inverse correlations between hypoxia-marker staining and Rad51 expression by immunofluorescence in cervical and prostate cancer xenograft models. We propose the existence of a hypoxic phenotype in solid tumors, characterized by decreased expression of the critical DNA repair genes, Mlh1 and Rad51, representing a novel mechanism of acquired genetic instability in the tumor microenvironment and dysregulated DNA damage response in cancer cells.

Mechanism of cancer cell killing by cisplatin
Cisplatin is one of the most widely used cancer chemotherapy agents, but its mechanism of action is not fully understood. Current models suggest that cell killing by cisplatin occurs in a cell-autonomous manner via formation of platinum-DNA adducts that, if not removed by DNA repair, block transcription and replication. We have found that there is a separate cell-interdependent pathway of cisplatin killing in which damaged cells can transmit a death signal to neighboring cells. This signal is produced within the damaged cell by the kinase function of the Ku70, Ku80, and DNA-PK complex and is conveyed to the recipient cell by direct cell-to-cell communication through gap junctions. Our findings suggest that DNA-PK activity and gap junction expression in human cancers may influence the clinical response to cisplatin. In addition, strategies to manipulate these cellular components in conjunction with cisplatin treatment may provide new approaches to cancer therapy.

DNA repair and mutagenesis in transgenic mice
We are carrying out mutagenesis studies using a lambda phage vector construct as a chromosomal shuttle vector in transgenic mice and mouse cells. We have determined that p53 overexpression can lessen mutagenesis by UV light, and we have examined the spectrum of x-ray-induced point mutations in mouse cells. In transgenic mice, we have found that locus specific effects can profoundly influence the mutation frequency in a reporter gene, and we have begun to study tissue-dependent variations in the pattern of spontaneous mutagenesis. Recently, we have created doubly transgenic mice carrying not only the lambda shuttle vector for reporting mutations but also a targeted disruption of the mouse PMS2 gene, a homolog of the E. coli mutL gene involved in mismatch repair. The human homolog of this gene has been associated with hereditary colon cancer. We are examining genetic instability in these mice using the lambda vector system. Preliminary work has shown elevated levels of mutation in all tissues tested, in contrast to the limited tissue distribution of cancer in the animals, a difference which highlights the complexity of cancer etiology.

  • Gene targeting and gene therapy for human genetic diseases via triple helix formation.
  • Tumor hypoxia, genetic instability, and cancer therapy.
  • DNA repair and mutagenesis in transgenic mice.

Selected Publications

Full List of PubMed Publications

Edit this profile

Contact Info

Peter M. Glazer, MD, PhD
Patient Care Location
Yale Therapeutic RadiologySmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste Smilow Lower Level

New Haven, CT 06511
View on map...
Office Location
Yale Therapeutic RadiologyHunter Building
15 York Street, Ste HRT 140A

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208040
New Haven, CT 06520-8040

Glazer Lab